Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1988 Apr;77:55–62. doi: 10.1289/ehp.887755

Comparative biology of test species.

E J Calabrese 1
PMCID: PMC1474542  PMID: 3289908

Abstract

This paper assesses the capacity of animal models to predict human response to carcinogenic agents with consideration for the heterogeneity of humans. It is widely accepted that human susceptibility to toxic substances, including carcinogens, is highly variable. Conventional rodent models are usually highly inbred and valued for their ability to display characteristic homogeneity. Current practice assumes that the homogeneity of response to toxic agents, including carcinogens, in the rodent model will be representative of humans. The issue then becomes, To which of the broad spectrum of human responses are specific animal models likely to be related? This paper examines the extent of human heterogeneity over a broad range of biochemical characteristics (e.g., aryl hydrocarbon hydroxylase activity, epoxide hydrase activity, beta-glucuronidase activity, debrisoquine hydroxylation, DNA-adduct formation) with emphasis on those biochemical characteristics that affect responses to carcinogens. Examples are presented to compare the heterogeneity of selected animal models for these biochemical characteristics as they relate to the spectrum of human responses noted above. The paper presents a theoretical perspective for determining to which part of the human population response spectrum common animal models are most likely to be extrapolated.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Dabbagh S. G., Idle J. R., Smith R. L. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol. 1981 Mar;33(3):161–164. doi: 10.1111/j.2042-7158.1981.tb13740.x. [DOI] [PubMed] [Google Scholar]
  2. Autrup H., Barrett L. A., Jackson F. E., Jesudason M. L., Stoner G., Phelps P., Trump B. F., Harris C. C. Explant culture of human colon. Gastroenterology. 1978 Jun;74(6):1248–1257. [PubMed] [Google Scholar]
  3. Autrup H., Schwartz R. D., Essigmann J. M., Smith L., Trump B. F., Harris C. C. Metabolism of aflatoxin B1, benzo[a]pyrene, and 1,2-dimethylhydrazine by cultured rat and human colon. Teratog Carcinog Mutagen. 1980;1(1):3–13. doi: 10.1002/tcm.1770010103. [DOI] [PubMed] [Google Scholar]
  4. Autrup H., Wefald F. C., Jeffrey A. M., Tate H., Schwartz R. D., Trump B. F., Harris C. C. Metabolism of benzo[a]pyrene by cultured tracheobronchial tissues from mice, rats, hamsters, bovines and humans. Int J Cancer. 1980 Feb 15;25(2):293–300. doi: 10.1002/ijc.2910250219. [DOI] [PubMed] [Google Scholar]
  5. DEVADATTA S., GANGADHARAM P. R., ANDREWS R. H., FOX W., RAMAKRISHNAN C. V., SELKON J. B., VELU S. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587–598. [PMC free article] [PubMed] [Google Scholar]
  6. Daniel F. B., Schut H. A., Sandwisch D. W., Schenck K. M., Hoffmann C. O., Patrick J. R., Stoner G. D. Interspecies comparisons of benzo(a)pyrene metabolism and DNA-adduct formation in cultured human and animal bladder and tracheobronchial tissues. Cancer Res. 1983 Oct;43(10):4723–4729. [PubMed] [Google Scholar]
  7. Dourson M. L., Stara J. F. Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol. 1983 Sep;3(3):224–238. doi: 10.1016/0273-2300(83)90030-2. [DOI] [PubMed] [Google Scholar]
  8. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Glowinski I. B., Radtke H. E., Weber W. W. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol Pharmacol. 1978 Sep;14(5):940–949. [PubMed] [Google Scholar]
  10. Harris C. C., Autrup H., Connor R., Barrett L. A., McDowell E. M., Trump B. F. Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. Science. 1976 Dec 3;194(4269):1067–1069. doi: 10.1126/science.982061. [DOI] [PubMed] [Google Scholar]
  11. Harris C. C., Mulvihill J. J., Thorgeirsson S. S., Minna J. D. Individual differences in cancer susceptibility. Ann Intern Med. 1980 Jun;92(6):809–825. doi: 10.7326/0003-4819-92-6-809. [DOI] [PubMed] [Google Scholar]
  12. Idle J. R., Smith R. L. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979;9(2):301–317. doi: 10.3109/03602537908993896. [DOI] [PubMed] [Google Scholar]
  13. Lombardo A., Goi G. C., Marchesini S., Caimi L., Moro M., Tettamanti G. Influence of age and sex on five human plasma lysosomal enzymes assayed by automated procedures. Clin Chim Acta. 1981 Jun 18;113(2):141–152. doi: 10.1016/0009-8981(81)90148-0. [DOI] [PubMed] [Google Scholar]
  14. Lower G. M., Jr, Bryan G. T. Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem Pharmacol. 1973 Jul 1;22(13):1581–1588. doi: 10.1016/0006-2952(73)90024-5. [DOI] [PubMed] [Google Scholar]
  15. Lower G. M., Jr, Bryan G. T. Enzymic deacetylation of carcinogenic arylacetamides by tissue microsomes of the dog and other species. J Toxicol Environ Health. 1976 Jan;1(3):421–432. doi: 10.1080/15287397609529341. [DOI] [PubMed] [Google Scholar]
  16. Lower G. M., Jr, Nilsson T., Nelson C. E., Wolf H., Gamsky T. E., Bryan G. T. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect. 1979 Apr;29:71–79. doi: 10.1289/ehp.792971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Maire I., Mandon G., Zabot M. T., Mathieu M., Guibaud P. Beta-glucuronidase deficiency: enzyme studies in an affected family and prenatal diagnosis. J Inherit Metab Dis. 1980;2(2):29–34. doi: 10.1007/BF01799071. [DOI] [PubMed] [Google Scholar]
  18. Mbanefo C., Bababunmi E. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica. 1980 Nov;10(11):811–818. doi: 10.3109/00498258009033811. [DOI] [PubMed] [Google Scholar]
  19. Mitchell J. R., Zimmerman H. J., Ishak K. G., Thorgeirsson U. P., Timbrell J. A., Snodgrass W. R., Nelson S. D. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976 Feb;84(2):181–192. doi: 10.7326/0003-4819-84-2-181. [DOI] [PubMed] [Google Scholar]
  20. Oesch F., Jerina D. M., Daly J. W., Rice J. M. Induction, activation and inhibition of epoxide hydrase: an anomalous prevention of chlorobenzene-induced hepatotoxicity by an inhibitor of epoxide hydrase. Chem Biol Interact. 1973 Mar;6(3):189–202. doi: 10.1016/0009-2797(73)90071-9. [DOI] [PubMed] [Google Scholar]
  21. Oesch F. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica. 1973 May;3(5):305–340. doi: 10.3109/00498257309151525. [DOI] [PubMed] [Google Scholar]
  22. Oesch F., Schmassmann H., Bentley P. Specificity of human, rat and mouse skin epoxide hydratase towards K-region epoxides of polycyclic hydrocarbons. Biochem Pharmacol. 1978 Jan 1;27(1):17–20. doi: 10.1016/0006-2952(78)90251-4. [DOI] [PubMed] [Google Scholar]
  23. Pelkonen O., Kaltiala E. H., Kärki N. T., Jalonen K., Pyörälä K. Properties of benzpyrene hydroxylase from human liver and comparison with the rat, rabbit and guinea-pig enzymes. Xenobiotica. 1975 Aug;5(8):501–509. doi: 10.3109/00498257509056120. [DOI] [PubMed] [Google Scholar]
  24. Propping P. Pharmacogenetics. Rev Physiol Biochem Pharmacol. 1978;83:123–173. doi: 10.1007/3-540-08907-1_4. [DOI] [PubMed] [Google Scholar]
  25. Stula E. F., Barnes J. R., Sherman H., Reinhardt C. F., Zapp J. A., Jr Urinary bladder tumors in dogs from 4,4'-methylene-bis (2-chloroaniline) (MOCA). J Environ Pathol Toxicol. 1978 Sep-Oct;1(1):31–50. [PubMed] [Google Scholar]
  26. Walaszek Z., Hanausek-Walaszek M., Webb T. E. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumorigenesis by 2,5-di-O-acetyl-D-glucaro-1,4:6,3-dilactone, an in vivo beta-glucuronidase inhibitor. Carcinogenesis. 1984 Jun;5(6):767–772. doi: 10.1093/carcin/5.6.767. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES